NCT00733187

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.

Detailed description

This study is a pharmacokinetic study designed to evaluate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869. Triplicate ECG performed to determine the effect of ABT-869 on QT prolongation . Subjects may continue receiving linifanib after completion of the study.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	ABT-869	0.25 mg/kg

Timeline

• Start date: 2009-02-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2008-08-12
• Last updated: 2017-11-21